AR117426A1 - Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina - Google Patents
Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfinaInfo
- Publication number
- AR117426A1 AR117426A1 ARP190101256A ARP190101256A AR117426A1 AR 117426 A1 AR117426 A1 AR 117426A1 AR P190101256 A ARP190101256 A AR P190101256A AR P190101256 A ARP190101256 A AR P190101256A AR 117426 A1 AR117426 A1 AR 117426A1
- Authority
- AR
- Argentina
- Prior art keywords
- buprenorphine
- crystalline forms
- acyl
- long
- injectable formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
- C07D489/04—Salts; Organic complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670714P | 2018-05-11 | 2018-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117426A1 true AR117426A1 (es) | 2021-08-04 |
Family
ID=68466685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101256A AR117426A1 (es) | 2018-05-11 | 2019-05-10 | Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11524965B2 (https=) |
| EP (1) | EP3790881B1 (https=) |
| JP (3) | JP7421804B2 (https=) |
| KR (2) | KR102839314B1 (https=) |
| CN (1) | CN111954672B (https=) |
| AR (1) | AR117426A1 (https=) |
| AU (1) | AU2019266795B2 (https=) |
| BR (1) | BR112020016576A2 (https=) |
| CA (1) | CA3089256C (https=) |
| MX (1) | MX2020008471A (https=) |
| NZ (1) | NZ766474A (https=) |
| TW (1) | TWI838372B (https=) |
| WO (1) | WO2019214726A1 (https=) |
| ZA (1) | ZA202004582B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020016576A2 (pt) | 2018-05-11 | 2020-12-15 | Alar Pharmaceuticals Inc. | Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina |
| GB202019594D0 (en) * | 2020-12-11 | 2021-01-27 | Univ London Queen Mary | Sustained release formulations of crystalline drugs |
| CN117999079A (zh) * | 2021-08-20 | 2024-05-07 | 苏州恩华生物医药科技有限公司 | 一种包含塞纳布啡的药物组合物 |
| IL317873A (en) * | 2022-06-24 | 2025-02-01 | Alar Pharmaceuticals Inc | Stable pharmaceutical composition of buprenorphine and method of preparation and use thereof |
| CN115317453A (zh) * | 2022-09-01 | 2022-11-11 | 广东嘉博制药有限公司 | 一种缓释微球制剂及其制备方法与用途 |
| EP4719414A2 (en) * | 2023-06-02 | 2026-04-08 | Board of Regents of the University of Nebraska | Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO121631B1 (ro) | 1999-08-27 | 2008-01-30 | Southern Research Institute | Compoziţie cu buprenorfină şi utilizarea acesteia pentru reducerea consumului de heroină şi/sau alcool |
| DE60329515D1 (de) | 2002-10-25 | 2009-11-12 | Euro Celtique Sa | Analoga und prodrugs von buprenorphin |
| CN1263760C (zh) * | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物 |
| DE60224288T2 (de) | 2002-11-25 | 2009-04-16 | Chi Mei Foundation Medical Center | Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel |
| JP2004175706A (ja) * | 2002-11-26 | 2004-06-24 | Chi Mei Foundation Medical Center | 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物 |
| WO2005117830A1 (en) | 2004-06-04 | 2005-12-15 | Camurus Ab | Liquid depot formulations |
| GB0606124D0 (en) | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
| US9272044B2 (en) * | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| GB2481018B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| FR2975912B1 (fr) * | 2011-05-30 | 2013-06-14 | Flamel Tech Sa | Composition a liberation controlee de buprenorphine |
| CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| EP2970188A4 (en) | 2013-03-15 | 2016-10-19 | Vm Therapeutics Llc | NOVEL CRYSTALLINE FORMS |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| GB201404139D0 (en) * | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| CN107660207B (zh) * | 2015-03-10 | 2020-09-29 | 罗德科技公司 | 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法 |
| TWI743193B (zh) * | 2016-09-13 | 2021-10-21 | 昱展新藥生技股份有限公司 | 丁基原啡因緩釋製劑 |
| BR112020016576A2 (pt) | 2018-05-11 | 2020-12-15 | Alar Pharmaceuticals Inc. | Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina |
-
2019
- 2019-05-10 BR BR112020016576-0A patent/BR112020016576A2/pt unknown
- 2019-05-10 AU AU2019266795A patent/AU2019266795B2/en active Active
- 2019-05-10 KR KR1020237020398A patent/KR102839314B1/ko active Active
- 2019-05-10 KR KR1020207035014A patent/KR20210021459A/ko not_active Ceased
- 2019-05-10 NZ NZ766474A patent/NZ766474A/en unknown
- 2019-05-10 US US16/981,745 patent/US11524965B2/en active Active
- 2019-05-10 CA CA3089256A patent/CA3089256C/en active Active
- 2019-05-10 CN CN201980023678.2A patent/CN111954672B/zh active Active
- 2019-05-10 JP JP2020561817A patent/JP7421804B2/ja active Active
- 2019-05-10 EP EP19799555.8A patent/EP3790881B1/en active Active
- 2019-05-10 WO PCT/CN2019/086449 patent/WO2019214726A1/en not_active Ceased
- 2019-05-10 MX MX2020008471A patent/MX2020008471A/es unknown
- 2019-05-10 TW TW108116576A patent/TWI838372B/zh active
- 2019-05-10 AR ARP190101256A patent/AR117426A1/es unknown
-
2020
- 2020-07-23 ZA ZA2020/04582A patent/ZA202004582B/en unknown
-
2022
- 2022-08-26 US US17/896,280 patent/US12522610B2/en active Active
-
2023
- 2023-05-15 JP JP2023079918A patent/JP2023106478A/ja active Pending
-
2025
- 2025-04-28 JP JP2025074417A patent/JP2025121948A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019214726A1 (en) | 2019-11-14 |
| US20210122756A1 (en) | 2021-04-29 |
| TW202016117A (zh) | 2020-05-01 |
| TWI838372B (zh) | 2024-04-11 |
| JP2023106478A (ja) | 2023-08-01 |
| JP2025121948A (ja) | 2025-08-20 |
| JP7421804B2 (ja) | 2024-01-25 |
| JP2021522306A (ja) | 2021-08-30 |
| US20230002399A1 (en) | 2023-01-05 |
| EP3790881A4 (en) | 2022-03-09 |
| US11524965B2 (en) | 2022-12-13 |
| EP3790881A1 (en) | 2021-03-17 |
| CA3089256A1 (en) | 2019-11-14 |
| AU2019266795B2 (en) | 2023-02-09 |
| ZA202004582B (en) | 2023-01-25 |
| CN111954672A (zh) | 2020-11-17 |
| US12522610B2 (en) | 2026-01-13 |
| AU2019266795A1 (en) | 2020-08-13 |
| BR112020016576A2 (pt) | 2020-12-15 |
| NZ766474A (en) | 2023-03-31 |
| KR20210021459A (ko) | 2021-02-26 |
| KR102839314B1 (ko) | 2025-07-29 |
| EP3790881B1 (en) | 2026-04-15 |
| KR20230093535A (ko) | 2023-06-27 |
| CN111954672B (zh) | 2023-09-01 |
| MX2020008471A (es) | 2020-09-25 |
| CA3089256C (en) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117426A1 (es) | Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina | |
| CL2020002866A1 (es) | Compuestos de heteroaril tetracíclicos | |
| CY1118191T1 (el) | Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης | |
| MX2018009257A (es) | Derivados de benzimidazol como moduladores de ror-gamma. | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2019003309A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| NI201900119A (es) | Derivados de indolina sustitudos como inhibidores de la replicación vírica de dengue | |
| CY1119817T1 (el) | Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| AR069552A1 (es) | Formulaciones para el tratamiento de semillas y metodos de uso | |
| EA201990501A1 (ru) | Фармацевтическая композиция | |
| UY38174A (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros compuestos relacionados, como inhibidores del complemento | |
| CO2019010292A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CY1124016T1 (el) | Φαρμακοτεχνικες μορφες οπιοειδων | |
| MX2019003099A (es) | Composicion farmaceutica. | |
| ECSP20057847A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| MX387969B (es) | Composiciones y compuestos terapéuticos, y métodos para su uso. | |
| CO2023008949A2 (es) | Forma cristalina de tolebrutinib, método de preparación y uso de la misma | |
| MX382489B (es) | Combinacion farmaceutica que comprende un agonista selectivo del receptor s1p1. | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2022003353A1 (es) | Composiciones farmacéuticas de pralsetinib | |
| MY206893A (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| CL2019000624A1 (es) | Formulaciones de buprenorfina de liberación sostenida. | |
| MX390384B (es) | Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina. | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. |